Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Rebecca Zisser/Axios

The gene editing tool CRISPR-Cas9 may cause large deletions and rearrange the DNA it is targeting in some cases, according to a new U.K. study published in Nature Biotechnology Monday.

Why it matters: Scientists hope CRISPR can one day be used to treat cancer, HIV, haemophilia and sickle cell disease. But this and other recent studies find it can cause unintended edits, and possibly trigger cancer.

"The DNA chaos that CRISPR unleashes has been 'seriously underestimated,'” study author and geneticist Allan Bradley of U.K.'s Wellcome Sanger Center tells STAT. “This should be a wake-up call.”

What they did: The three scientists edited two types of mouse cells and human cells and sequenced long stretches of the DNA in the edited sections.

What they found: Deletions of up to several thousand DNA bases were seen, along with complex rearrangements at the target site, which means neighboring genes could be affected or cell function altered, the authors said.

  • In one experiment, they found two-thirds of the edited genes showed expected levels of small unwanted changes, but 20% of them had large unplanned deletions.
  • "As genetic damage is frequent, extensive and undetectable by the short-range PCR assays that are commonly used, comprehensive genomic analysis is warranted to identify cells with normal genomes before patient administration," the authors warned in their study.
  • Yes but: Patrick Hsu, principal investigator and Salk Helmsley Fellow at the Salk Institute for Biological Studies, tells Axios in an emailed statement, "It’s worth noting that the large deletions found in this study are still in the single digit kilobase range, so they are still mostly local events that may not necessarily affect neighboring genes."

More reactions:

  • “I do believe the findings are robust,” Gaetan Burgio of the Australian National University, who has debunked previous studies questioning the method’s safety, tells New Scientist. “This is a well-performed study and fairly significant.”
  • Very careful work is needed “to verify that the alterations to the DNA sequence are those, and only those, that had been designed to occur,” stem cell expert Robin Lovell-Badge told Reuters.“But the results give no reason to panic or to lose faith in the methods when they are carried out by those who know what they are doing.”

What's next: "This study raises important parameters that should be tracked and monitored for therapeutic applications. There are clear paths forward for each of these potential challenges, but both the challenges and solutions are still at the blackboard level. We won’t necessarily know their relative importance until we are in the clinic," says Hsu, who was not part of this study.

Go deeper

10 hours ago - Politics & Policy

Biden explains justification for Syria strike in letter to Congress

Photo: Chris Kleponis/CNP/Bloomberg via Getty Images

President Biden told congressional leadership in a letter Saturday that this week's airstrike against facilities in Syria linked to Iranian-backed militia groups was consistent with the U.S. right to self-defense.

Why it matters: Some Democrats, including Sens. Tim Kaine (D-Va.) and Chris Murphy (D-Conn.) and Rep. Ro Khanna (D-Calif.), have criticized the Biden administration for the strike and demanded a briefing.

11 hours ago - Health

FDA authorizes Johnson & Johnson's one-shot COVID-19 vaccine for emergency use

Photo: Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

The Food and Drug Administration on Saturday issued an emergency use authorization for Johnson & Johnson's one-shot coronavirus vaccine.

Why it matters: The authorization of a third coronavirus vaccine in the U.S. will help speed up the vaccine rollout across the country, especially since the J&J shot only requires one dose as opposed to Moderna and Pfizer-BioNTech's two-shot vaccines.

Updated 11 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios